Skip to main content
SpringerLink
Log in

Sequential high-dose methotrexate, 5-fluorouracil, and doxorubicin for treatment of advanced pancreatic cancer

  • Rapid Communication
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Summary

A phase II trial of sequential high-dose methotrexate, 1500 mg/m2, and 5-fluorouracil, 1500 mg/m2 intravenously on day 1, plus doxorubicin, 30 mg/m2 i. v. on day 14, has been undertaken in patients with locally advanced or metastatic adenocarcinoma of the pancreas. Of 25 evaluable patients there were 1 complete response and 3 partial responses for an overall response rate of 16% (95% confidence interval 5%–36%). The median survival of all patients was 6.7 months (range 1–17 months). There was one treatment-related death due to pancytopenia and sepsis. In all other patients therapy was generally well-tolerated. We conclude that this combination protocol has only modest activity in the treatment of advanced pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Djerassi I, Kim JS, Suvansri U (1974) “Pulse” methotrexate and citrovorum factor “rescue” in common solid tumors (including lung and pancreas ca) of the adult. Proc Am Assoc Cancer Res Am Soc Clin Oncol 78

  • Kalser MH, Ellenberg SS (Gastrointestinal Tumor Study Group) (1985) Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899–903

    Google Scholar 

  • O'Connell MJ (1985) Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol 3:1032–1039

    Google Scholar 

  • WHO Handbook for reporting results of cancer treatment (1979) WHO offset publication no. 48. Nyhoff, The Hague

    Google Scholar 

  • Wils J, Klein HO, Bleiberg H, Buyse M, Wagener DT, Conroy T, Diaz-Rubio E, Hillen H, Korsten FW, Reis H, Duez N (1989) EORTC 40851: sequential high dose methotrexate (MTX) and 5-fluorouracil (F) combined with adriamycin (A) (FAMTX) versus F, A, and mitomycin C (M) (FAM) in advanced gastric cancer. Proc Am Soc Clin Oncol 8:109

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology II, University Medical School, Garnisongasse 13, A-1090, Vienna, Austria

    W. Scheithauer & Ch. Mueller

  2. Department of Surgery I, University Medical School, Garnisongasse 13, A-1090, Vienna, Austria

    J. Funovics

  3. Department of Internal Medicine II, University Medical School, Garnisongasse 13, A-1090, Vienna, Austria

    H. Ludwig

Authors
  1. W. Scheithauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Funovics
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ch. Mueller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scheithauer, W., Funovics, J., Mueller, C. et al. Sequential high-dose methotrexate, 5-fluorouracil, and doxorubicin for treatment of advanced pancreatic cancer. J Cancer Res Clin Oncol 116, 132–133 (1990). https://doi.org/10.1007/BF01612666

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01612666

Key words

Search

Navigation